Research analysis

September 27, 2026 Pyrvinium, gastric metaplasia, and the Wnt blind spot in organoid screens

A randomized phase II trial at Duke asks whether two weeks of pyrvinium can reverse gastric intestinal metaplasia, with patient organoids as an in-vitro mirror. The catch: gastric organoids are Wnt-dependent cultures, and pyrvinium blocks Wnt.

September 27, 2026 Tumor organoids as living bait for TCR-T cell selection

A long-running phase I trial in Guangzhou uses patient tumor organoids to screen tumor-reactive T cells, clone their TCRs, and reinfuse them as engineered cells. The organoid is on the critical path of the manufacturing process.

September 26, 2026 The trial that wrote an organoid cutoff into its resistance rule

NCT07647263 at Soochow University gives HER2-positive breast cancer patients two cycles of THP, then defines inadequate response as under 50 percent tumor shrinkage or failing an organoid killing threshold, and switches non-responders to the ADC SHR-A1811. The design embeds an organoid assay in an interventional decision for the first time in this class, and its threshold provenance is nowhere disclosed.

September 26, 2026 A macrophage-targeting program with T-cell readouts

NCT05955196 at Institut Paoli-Calmettes is building small-molecule inhibitors of the CD47-SIRPalpha myeloid checkpoint and testing them on patient-derived colon organoids that the team says retain myeloid stroma. The registered immune endpoints, however, measure T-cell activity, not the phagocytosis the drug is meant to restore.

September 26, 2026 The spondyloarthritis trial that measures survival, not the axis

A Gemelli IRCCS registry entry proposes paired synovial and intestinal organoids to model the spondyloarthritis gut-joint axis in 60 patients. Its registered primary outcome is an ATP viability assay, and the record has sat in UNKNOWN status for over two years.

September 25, 2026 Cell therapy leans on organoid relapse forensics

The ResCPa trial will test CD318-targeted CAR-T cells in 38 patients with metastatic pancreatic cancer, and its translational program leans on patient-derived organoids and xenografts to study cytotoxicity, antigen recognition and resistance. That makes the organoid the failure-analysis instrument for cell therapy, a role with real power and a real blind spot.

September 25, 2026 When organoids gate a pivotal trial

A completed phase IIb trial of the triple CFTR modulator diponecaftor enrolled only cystic fibrosis patients whose intestinal organoids had responded to the drug in the HIT-CF screening program, alongside a randomly selected comparator group. It is the cleanest test yet of the organoid biomarker claim, and it carries a generalization warning for everyone building drug discovery on organoid models.

September 25, 2026 Organoid-guided therapy meets its fairest test

A recruiting phase II trial at Guangdong Provincial People's Hospital will randomize 252 previously treated HER2-negative advanced breast cancer patients to organoid-guided treatment or physician's choice, with both arms drawing from the same ten-drug menu. Holding the menu fixed while varying only the selection method is the cleanest design the field has fielded, and the remaining weaknesses are where every such trial will be attacked.

September 24, 2026 The organoid assay as a logistics problem

A Swiss phase II trial in intermediate-risk bladder cancer treats the organoid drug screen as a logistics problem: 31 patients, a ten-day culture, and a primary endpoint that asks only whether the assay can deliver a drug selection. That humility is the most instructive design choice in the current wave of organoid-guided trials.

September 24, 2026 The gut-liver axis, rebuilt in a dish

A recruiting study at Gemelli IRCCS in Rome plans to derive hepatocellular-carcinoma organoids from surgical tissue, reconstitute them with each patient's gut microbiota and immune cells, and test immunotherapy and kinase inhibitors against them. Its primary endpoint is a correlation with disease-free and overall survival. The ambition is right; the generalization gap is the story.

September 24, 2026 When organoid-guided therapy meets trial design

A newly registered phase II trial at a Shanghai hepatobiliary hospital will use patient-derived organoid drug sensitivity testing to choose systemic therapy for 88 patients with unresectable biliary tract cancer. The design assigns patients to the organoid-guided group or standard therapy by patient preference, not randomization. That single choice determines whether the trial can ever answer its own question.

September 23, 2026 Cilium disassembly as a glioblastoma target, organoid-tested

A completed single-center study in Rome tested a mechanistic bet: that the primary cilium's disassembly machinery, including the kinase Nek2, is a druggable dependency of glioblastoma stem cells. The work used patient-derived glioblastoma stem cells and brain organoids as its ex vivo invasion assay, and registered the correlation between cilia-gene modulation and tumor growth as its primary outcome. Results were never posted.

September 23, 2026 Liver organoids as the phenotype anchor for MASLD genetics

A newly registered Milan study of an estimated 35,500 people will test whether lipid-droplet biology is the early driver of progression from fatty liver disease to fibrosis and liver cancer. Human liver organoids derived from patients are one of six registered interventions, tasked with measuring lipid-droplet morphology and kinetics that cannot be read from a biopsy. The primary endpoints are hard clinical events, so the organoid arm must prove its incremental value.

September 23, 2026 Pediatric immune organoids, with take rate as the endpoint

A Gustave Roussy study is reprogramming skin biopsies from children with brain tumors, renal tumors, neuroblastoma and sarcomas into iPSC-derived immune organoids and engrafting each patient's tumor into them. Its registered primary endpoint is not a biological result but the proportion of viable, exploitable organoids achieved, which makes the platform's failure rate the thing being measured.

September 22, 2026 What a terminated feasibility study says about organoid platforms

NCT04561453 was designed the way platform-medicine studies should be: its primary endpoint was the success rate of organoid culture and drug screening within 12 weeks of surgery, alongside circulating tumor DNA quantification. It terminated in April 2025 because funding ended, after enrolling 14 patients across more than four years, and no results have ever been posted.

September 22, 2026 A bladder-cancer trial pair that commits to overall survival

Qilu Hospital has registered a matched pair of trials testing organoid-guided perioperative chemotherapy for muscle-invasive bladder cancer, one neoadjuvant and one adjuvant, both comparing against empirically chosen regimens. Both put one-, three- and five-year overall survival as the primary endpoint, which is exactly what the organoid field needs and exactly what makes the answer six years away.

September 22, 2026 A 200-patient bet on organoid-guided rare-tumor care

NCT06692491 is a phase II, multicenter, non-randomized trial in China that will treat advanced rare cancers using regimens chosen by a molecular tumor board from organoid drug screens and next-generation sequencing, against a guideline standard-treatment arm. Its primary endpoint is objective response rate at eight weeks, and its design quietly concedes most of the objections a skeptic would raise.

September 21, 2026 Stopped at n=2: GSK's organoid biomarker bet

NCT06405230 was GlaxoSmithKline's attempt to credential patient-derived organoids as pharmacodynamic biomarkers, alongside extracellular vesicles and zirconium-89 PD-L1 PET, in recurrent lung cancer. The record now reads terminated, operational challenges, two participants enrolled. That is a data point the organoid credentialing debate should take seriously.

September 21, 2026 Organoids versus hypertension: an epithelial readout

NCT04497727 grew gut organoids from colonic biopsies of 16 hypertensive and 19 normotensive adults to ask whether the gut epithelium carries a blood-pressure signature. The completed study's careful de-confounding design is a model worth copying; its nearly empty results posting is a model worth avoiding.

September 21, 2026 Six percent: an organoid-motivated combo meets phase II

A phase II trial of cabozantinib plus atezolizumab in refractory metastatic pancreatic cancer was motivated in part by promising results in patient-derived pancreas organoids. Results posted in September 2026 show a 6 percent response proportion, a hard number the organoid field should absorb.

September 20, 2026 The breast cancer study that banks tumors and reads their mail

An Italian prospective study of 240 breast cancer patients makes organoid establishment rate its primary endpoint and plans to read tumor-derived extracellular vesicles as predictors of response to neoadjuvant chemotherapy. It reframes the organoid from a miniature patient into a biomarker production platform, with consequences the field has not fully priced in.

September 20, 2026 Grown hot: organoids tasked with predicting HIPEC response

A German multicenter study grows organoids from the peritoneal metastases of gastric and colorectal cancer patients and tests chemotherapy at the elevated temperatures used in HIPEC. It is an attempt to make an organoid predict not a drug, but a surgical procedure, and it exposes a credentialing gap the field has not closed.

September 20, 2026 Twenty patients, one arm, and the organoid-matching bet in lung cancer

A Henan Cancer Hospital study treats 20 patients with relapsed, drug-resistant non-small cell lung cancer using whichever approved drug their tumor organoids respond to most strongly. The design distills the organoid-matching bet into its purest form, and its quietly decaying registry record shows what that bet can never establish.

September 19, 2026 Organoids as the tiebreaker in CF diagnosis

A prospective study at Royal Brompton Hospital in London will recruit eighty adults across three cohorts and compare rectal-organoid CFTR function against sweat chloride, nasal potential difference and intestinal current measurements. Its target is the awkward middle of cystic fibrosis diagnosis: people with rare variants and non-diagnostic standard tests, for whom the organoid readout may decide both the diagnosis and access to modulator drugs.